Galiximab
| Galiximab | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Galiximab is a monoclonal antibody that was under development for the treatment of certain types of cancer, specifically non-Hodgkin lymphoma. It targets the CD80 molecule, a protein expressed on the surface of some B-cells and tumor cells, which is involved in the regulation of immune response.
Development and Mechanism
Galiximab is a primatized antibody, meaning it is a hybrid molecule composed of both human and primate antibody sequences. This design aims to reduce the likelihood of the human immune system recognizing the antibody as foreign and developing an antibody response against it, which can limit the therapeutic efficacy and increase the risk of adverse effects.
The mechanism of action of galiximab involves binding to the CD80 molecule on the surface of B-cells. CD80 plays a critical role in the activation of T-cells, which are essential for immune surveillance against tumors. By targeting CD80, galiximab may help inhibit the growth of B-cell lymphomas, which rely on these interactions for survival and proliferation.
Clinical Trials
Galiximab was evaluated in several clinical trials, often in combination with other chemotherapy agents. These studies aimed to assess its safety and efficacy in patients with non-Hodgkin lymphoma. However, as of the last updates, it has not received approval from regulatory bodies such as the Food and Drug Administration (FDA) for public use.
Current Status
Research on galiximab has been limited, and it is not currently available as a treatment option. The development may have been discontinued or paused due to various factors, including clinical trial results, strategic decisions by the developing company, or other regulatory issues.
See Also
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
